Journal of Archives in Military Medicine
Volume 14 · Issue 3 · e173371

OPEN PEER REVIEW

Cytotoxicity of Silver Nanoparticles and *Achillea millefolium* in MCF7 Breast Cancer Cells

Yasman Amini Khalaf Khanqah, Azadeh Karami Robati

SUBMITTED	ACCEPTED	DOI
7 Jul 2026	18 Sep 2026	10.69107/jamm-173371

About this report

This open peer review (OPR) report shows the public comments made on this article during peer review, by the reviewers, the associate editor and the editor-in-chief, for every revision round, together with the authors' replies. Comments appear only with the consent of the people who wrote them. Reviewers who chose to sign their report are named; the others are shown as "Referee". Comments are edited for language only, and confidential remarks to the editors are not included.

More about open peer review: brieflands.com/knowledgebase/opr

Contents

1 **Original submission** Referee 1, Associate Editor, Editor-in-Chief 2

1 Original submission

3 comments · 24 Aug 2026 – 29 Sep 2026

Referee 1 Reviewer

REJECT 24 Aug 2026

Dear Authors,

Thank you for submitting your manuscript entitled “Study of Toxicity Silver Nanoparticles and Achillea millefolium on MCF7 Breast Cancer Cell” to the Journal of Archives in Military Medicine.

After initial editorial assessment, I concluded that the manuscript falls outside the journal’s aims and scope. The study examines the in vitro anticancer activity of Achillea millefolium extract and silver nanoparticles against a breast cancer cell line but does not address military personnel, veterans, military healthcare, operational medicine, emergency or disaster medicine, or another clear military-health application.

I must therefore decline the manuscript without external peer review. This decision concerns journal scope rather than the potential scientific value of the work. You may wish to submit the manuscript to a journal specializing in cancer pharmacology, medicinal plants, nanomedicine, or experimental oncology.

Kind regards,
Scientific Reviewer

Associate Editor

ACCEPT 29 Sep 2026

Accepted with no comments

Editor-in-Chief

ACCEPT 29 Sep 2026

Accepted based on the AE's decision.